ArticleThe Lancet. Oncology2015

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Tony Reid et al.PubMed ↗Publisher ↗

No numbers read from the abstract.